felin
coronavirus
fcov
caus
agent
sever
system
diseas
felin
infecti
periton
fip
domest
wild
cat
fcov
classifi
serotyp
ii
type
fcov
domin
serotyp
approxim
worldwid
therefor
necessari
provid
antivir
agent
type
fcov
infect
studi
demonstr
itraconazol
icz
practic
use
fungal
infect
cat
inhibit
type
fcov
infect
icz
also
exhibit
antivir
effect
cell
viral
infect
suggest
icz
could
potenti
use
therapeut
felin
coronaviru
fcov
famili
coronavirida
genu
alphacoronaviru
envelop
singlestrand
positivesens
rna
viru
fcov
exist
two
differ
biotyp
felin
enter
coronaviru
fecv
felin
infecti
periton
viru
fipv
former
caus
mild
enter
usual
subclin
infect
latter
caus
highli
lethal
system
diseas
fip
although
antivir
drug
vaccin
fip
investig
method
establish
practic
use
furthermor
fcov
also
exist
two
serotyp
type
fcov
type
fecv
type
fipv
type
ii
fcov
type
ii
fecv
type
ii
fipv
serolog
genet
survey
show
type
fcov
domin
worldwid
previous
report
type
fcov
close
associ
cholesterol
throughout
viral
life
cycl
also
demonstr
cholesterol
transport
inhibitor
strongli
inhibit
type
fcov
infect
base
find
may
appli
therapeut
drug
fip
howev
knowledg
approv
veterinari
practic
use
use
treat
fip
pharmacokinet
pharmacodynam
safeti
studi
must
perform
cat
sever
candid
antivir
drug
target
type
fcov
identifi
howev
none
drug
scientif
demonstr
exhibit
therapeut
effect
fip
practic
use
solv
problem
desir
identifi
potent
antivir
agent
fcov
infect
among
drug
gener
use
cat
itraconazol
icz
classifi
azol
antifung
low
toxic
use
treat
fungal
infect
immunocompromis
patient
commonli
use
veterinarian
treat
fungal
infect
dog
cat
recent
icz
suggest
effect
enterovir
infect
polioviru
rhinoviru
coxsackieviru
previous
investig
antivir
effect
cholesterol
transport
inhibitor
includ
confirm
icz
inhibit
type
fcov
infect
howev
influenc
icz
fcov
infect
investig
detail
studi
examin
antivir
effect
icz
fcov
feli
catu
whole
fetu
fcwf
cell
sensit
type
fipv
type
ii
fipv
type
ii
fecv
use
icz
itorizol
purchas
janssen
pharmaceut
kk
tokyo
japan
solvent
icz
wv
hydroxypropylbetacyclodextrin
fujifilm
wako
pure
chemic
japan
contain
vv
propylen
glycol
vv
hydrochlor
acid
use
icz
adjust
mm
solvent
aliquot
store
use
mainten
medium
mem
use
dilut
icz
evalu
cytotox
effect
icz
solvent
cell
cell
viabil
measur
assay
describ
correspond
hohdatsu
vmaskitasatouacjp
school
veterinari
medicin
kitasato
univers
towada
aomori
japan
percent
cytotox
calcul
use
follow
formula
cytotox
od
icz
solvent
treat
cellsod
icz
solvent
untreat
cell
final
ph
diluent
icz
solvent
cytotox
concentr
cc
cytotox
concentr
cc
valu
icz
mean
se
mean
se
respect
figur
influenc
icz
infect
strain
type
fcov
fipvi
fipvi
fipvi
strain
type
ii
fcov
fipvii
cell
investig
confluent
cell
monolay
cultur
medium
contain
icz
indic
concentr
multipl
h
cell
wash
viru
moi
adsorb
onto
cell
h
wash
cell
cultur
carboxymethyl
cellulos
cmc
mem
mem
without
cmc
perform
plaqu
inhibit
assay
use
plastic
plate
necessari
clearli
prepar
plaqu
small
area
monolay
cell
cmcmem
appropri
agarmem
overlay
medium
plaqu
inhibit
assay
cell
cultur
cmcmem
incub
h
fix
stain
crystal
violet
solut
contain
buffer
formalin
result
plaqu
count
percentag
plaqu
inhibit
calcul
use
follow
formula
percentag
plaqu
inhibit
plaqu
number
compoundtr
cell
plaqu
number
compounduntr
cell
cell
cultur
mem
cultur
supernat
collect
h
postinfect
viru
titer
determin
titrat
assay
pretreat
icz
reduc
plaqu
format
type
fcov
dosedepend
manner
figur
plaqu
format
type
fcov
inhibit
icz
contrast
percentag
plaqu
inhibit
type
ii
fcov
slightli
affect
pretreat
icz
si
icz
viru
base
result
plaqu
inhibit
assay
cytotox
assay
shown
tabl
accord
titrat
assay
product
type
fcov
dosedepend
decreas
icz
figur
product
type
ii
fcov
slightli
decreas
icz
ad
next
investig
express
viral
protein
order
evalu
effect
icz
fcov
infect
cell
grown
labtek
chamber
slide
thermo
fisher
scientif
usa
confluent
cell
monolay
cultur
medium
contain
icz
h
cell
wash
viru
moi
adsorb
cell
h
wash
cell
cultur
mem
cell
monolay
incub
h
nucleocapsid
protein
level
determin
immunofluoresc
assay
ifa
describ
previous
recogn
fipv
n
protein
mab
mous
prepar
laboratori
use
nuclei
stain
dapi
dojindo
laboratori
japan
n
protein
level
fipvi
specif
decreas
cell
pretreat
icz
contrast
fipvi
pretreat
icz
affect
n
protein
level
fipvii
cell
figur
furthermor
examin
effect
icz
plaqu
format
infect
cell
fipvi
viru
moi
ad
cultur
adsorb
cell
h
wash
cell
cultur
mem
h
exchang
mem
cmcmem
contain
icz
cell
cultur
h
percentag
plaqu
inhibit
measur
describ
posttreat
icz
inhibit
fipvi
plaqu
format
degre
compar
pretreat
figur
contrast
percentag
plaqu
inhibit
fipvii
slightli
affect
posttreat
icz
type
fcov
infect
strongli
inhibit
cholesterol
transport
inhibitor
icz
report
inhibit
intracellular
cholesterol
transport
similar
therefor
figur
cytotox
effect
icz
cell
cell
viabil
measur
assay
describ
black
circl
indic
treatment
icz
white
circl
indic
treatment
solvent
solvent
control
solvent
concentr
icz
solut
serial
dilut
data
repres
three
independ
experi
semiconflu
cell
monolay
cultur
medium
contain
icz
fujifilm
wako
pure
chemic
japan
h
fix
stain
filipin
iiistain
cell
analyz
use
leica
microscop
la
x
integr
imag
system
leica
microsystem
germani
icz
induc
accumul
cellular
cholesterol
similar
figur
determin
whether
icz
affect
cellular
cholesterol
content
level
cholesterol
cell
measur
amount
intracellular
cholesterol
determin
use
amplex
red
cholesterol
assay
kit
molecular
probe
usa
follow
manufactur
instruct
neither
icz
decreas
cellular
cholesterol
level
figur
serotyp
icz
inhibit
type
fcov
infect
approxim
cat
fip
infect
type
fcov
would
reason
test
use
icz
antifipv
agent
hand
icz
affect
type
ii
fcov
suggest
antivir
effect
icz
differ
depend
serotyp
fcov
incid
type
ii
fipvinduc
fip
japan
taiwan
higher
europ
combin
icz
drug
necessari
countri
differ
note
result
plaqu
inhibit
viru
titrat
assay
virusinfect
cell
treat
icz
signific
inhibitori
effect
type
fipv
infect
observ
former
signific
inhibitori
effect
note
latter
sinc
plaqu
inhibit
assay
measur
infect
titer
parent
viru
wherea
viru
titrat
assay
measur
progeni
viru
find
suggest
icz
strongli
inhibit
parent
viru
infect
concentr
insuffici
inhibit
progeni
viru
product
howev
titer
produc
progeni
viru
result
plaqu
inhibit
assay
strongli
suggest
progeni
viru
infect
inhibit
cell
treat
icz
booth
et
al
previous
report
pharmacokinet
variabl
icz
cat
accord
report
peak
blood
concentr
cmax
ml
cat
treat
oral
icz
mg
kg
reach
cat
treat
oral
icz
twice
within
interv
present
studi
plaqu
format
viral
antigen
express
inhibit
cell
treat
icz
similar
effect
note
cell
treat
icz
infect
fipvi
suggest
administr
icz
mgkg
twice
daili
cat
diagnos
fip
may
decreas
viral
load
treatment
fungal
infect
cat
icz
administ
high
dose
mgkg
earli
phase
administr
icz
high
dose
earli
phase
may
also
exert
antivir
effect
fip
blood
alanin
aminotransferas
report
increas
highdos
icz
continu
symptom
improv
discontinu
drug
administr
recommend
veterinarian
use
icz
treatment
fip
follow
fungal
infect
treatment
protocol
cat
previous
report
inhibit
cholesterol
transport
type
fipv
infect
act
cholesterol
transport
niemannpick
protein
studi
inhibit
intracellular
cholesterol
transport
icz
confirm
accumul
cholesterol
cytoplasm
induc
icz
report
sever
studi
present
studi
mechan
clarifi
recent
report
icz
induc
cholesterol
accumul
lysosom
act
base
report
icz
may
inhibit
type
fcov
replic
via
mechan
addit
virus
type
fcov
icz
inhibit
infect
act
protein
exampl
report
icz
act
oxysterolbind
protein
osbp
inhibit
format
viral
replic
organel
enterovirus
site
replic
coronaviru
presum
associ
endoplasm
reticulum
er
deriv
structur
often
refer
doubl
membran
vesicl
dmv
unclear
whether
osbp
involv
format
viral
replic
organel
coronaviru
relationship
infect
type
fipv
osbp
need
investig
studi
confirm
icz
inhibit
infect
type
fipv
domin
strain
field
suggest
icz
appli
therapeut
drug
fip
fip
multicaus
diseas
involv
variou
risk
factor
virul
fcov
statu
immun
host
rout
viru
infect
take
fact
consider
plan
perform
clinic
trial
icz
use
cat
diagnos
fip
investig
combin
therapeut
drug
fip
time
